Veterinary peptide literature: what animal clinical evidence does and doesn't tell us

Veterinary pharmacology is its own discipline. The FDA's Center for Veterinary Medicine reviews and approves new animal drugs separately from human drugs, maintains a separate approved-products list (the Green Book), and has approved peptide-class molecules — gonadorelin for cattle reproduction, deslorelin for ovulation induction in mares — that are not approved for human use even when the molecular sequence is identical to a human-medicine analog. The veterinary peptide literature is large, methodologically real, and largely invisible to readers who land on a peptide page through human-biohacker channels.

It is also routinely invoked in those channels. "Trainers use TB-500 on racehorses" is one of the more durable practitioner-protocol arguments for the molecule. "BPC-157 was first characterized in rats by Sikiric's group, and rats are mammals, so the rat data should translate" is another. These claims are partially true and partially the kind of cross-species extrapolation that translational pharmacology spends its career being skeptical of. This dossier surveys what the veterinary peptide literature actually contains, where the regulated veterinary-medicine pathway sits, and what conclusions the evidence supports and does not support when the question shifts from animal to human.

The frame is not anti-veterinary. Veterinary medicine is a legitimate regulated field with its own pharmacology, its own approval pathway, its own pharmacokinetic literature, and its own clinical norms. The frame is anti-misuse-of-veterinary-data — the move from "this molecule is administered to racehorses by licensed veterinarians at a specific dose for a specific indication" to "therefore it works at biohacker doses in humans" is the kind of inference the published evidence does not support, and that inference is what this page is built around.